Loading...
Loading...
RFL| Name | Value |
|---|---|
| Revenues | 362.0K |
| Cost of Revenue | 31.0K |
| Gross Profit | 331.0K |
| Operating Expense | 6,173.0K |
| Operating I/L | -5,913.0K |
| Other Income/Expense | -549.0K |
| Interest Income | 472.0K |
| Pretax | -6,462.0K |
| Income Tax Expense | 2,411.0K |
| Net Income/Loss | -4,779.0K |
Rafael Holdings, Inc. operates in the pharmaceuticals and real estate sectors. The company leases commercial office space and a public garage while also focusing on the development and commercialization of therapies targeting metabolic differences between normal and cancer cells. Its lead drug candidate, CPI-613 (devimistat), is undergoing clinical trials for metastatic pancreatic cancer and r/r acute myeloid leukemia. The company generates revenue through leasing real estate assets and potentially through the future commercialization of its pharmaceutical products.
